文献速递治疗药物监测与药物基因组学特殊人群用药

CYP2D6对氟哌噻吨、氟哌啶醇、奋乃静和珠氯噻醇血清浓度的影响

Impact of CYP2D6 on serum concentrations of flupentixol, haloperidol, perphenazine and zuclopenthixol.
PubMed 文献 · Br J Clin Pharmacol · 2020-11-23

该研究从常规TDM数据库回顾性提取2005年3月至2019年5月CYP2D6基因分型患者的精神药物血清浓度,按基因型分为正常、中间和慢代谢者,用多变量混合模型分析CYP2D6表型对四种抗精神病药剂量调整血清浓度的影响。结果显示CYP2D6对奋乃静和珠氯噻醇代谢重要,对氟哌啶醇和氟哌噻吨影响较小或无影响。

要点

  • CYP2D6慢代谢者奋乃静剂量调整血清浓度较正常代谢者高3.9倍。
  • CYP2D6慢代谢者珠氯噻醇剂量调整血清浓度较正常代谢者高约1.5倍。
  • CYP2D6对氟哌啶醇和氟哌噻吨的剂量调整血清浓度影响较小或无影响。

核心结论

  • CYP2D6对奋乃静和珠氯噻醇的代谢重要,但对氟哌啶醇和氟哌噻吨不重要。
  • CYP2D6*41等位基因功能降低,接近无功能变异等位基因。

研究设计与样本

  • 回顾性研究,从常规TDM数据库提取2005年3月至2019年5月CYP2D6基因分型患者的数据。
  • 样本按CYP2D6基因型分为正常代谢者、中间代谢者和慢代谢者三个亚组。
  • 采用多变量混合模型分析CYP2D6表型对四种抗精神病药剂量调整血清浓度的影响。

主要发现

  • 奋乃静(564样本)慢代谢者和中间代谢者剂量调整血清浓度分别较正常代谢者高3.9倍和1.6倍(P < .001和P < .01)。
  • 珠氯噻醇(658样本)慢代谢者和中间代谢者剂量调整血清浓度分别较正常代谢者高约1.5倍和1.3倍(P < .01和P < .001)。
  • CYP2D6对氟哌啶醇(320样本)和氟哌噻吨(115样本)影响较小或无影响。
  • CYP2D6*1/*41基因型对奋乃静剂量调整血清浓度的影响与*1/null相似。

临床怎么用

  • 使用奋乃静或珠氯噻醇时,可考虑CYP2D6基因分型指导剂量调整。
  • CYP2D6慢代谢者使用奋乃静或珠氯噻醇时需警惕血清浓度升高。
  • 氟哌啶醇和氟哌噻吨的剂量调整可能无需常规考虑CYP2D6表型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To investigate the impact of cytochrome P450 2D6 (CYP2D6) on dose-adjusted serum concentrations of flupentixol, haloperidol, perphenazine and zuclopenthixol in a therapeutic drug monitoring (TDM) cohort of psychiatric patients. We also studied the functional impact of CYP2D6*41 on dose-adjusted serum concentrations in the perphenazine-treated patients. METHODS: Serum concentrations of flupentixol, haloperidol, perphenazine and zuclopenthixol from CYP-genotyped patients were extracted retrospectively from a routine TDM database in the period March 2005 to May 2019. Samples were divided into three CYP2D6 phenotype subgroups according to genotype; normal metabolizers (NMs), intermediate metabolizers (IMs) and poor metabolizers (PMs). The effect of CYP2D6 phenotype on dose-adjusted serum concentrations of the four antipsychotics was evaluated by multivariable mixed model analyses. RESULTS: Mean dose-adjusted serum concentrations of perphenazine (564 samples) were 3.9-fold and 1.6-fold higher in CYP2D6 PMs and IMs, respectively, compared with NMs (P < .001 and P < .01). For zuclopenthixol (658 samples), mean dose-adjusted serum concentrations were about 1.5-fold and 1.3-fold higher in CYP2D6 PMs and IMs, respectively, compared with NMs (P < .01 and P < .001). CYP2D6 was of minor or no importance to haloperidol (320 samples) and flupentixol (115 samples). In our data material, the genotype CYP2D6 *1/*41 appears to have a similar impact on dose-adjusted serum concentrations of perphenazine as *1/null (null = variant allele encoding no enzyme function). CONCLUSIONS: This study shows that CYP2D6 is important for the metabolism of perphenazine and zuclopenthixol, but not for haloperidol and flupentixol. The CYP2D6*41 allele appears to have a reduced function close to nonfunctional variant alleles.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Waade RB, Solhaug V, Høiseth G, et al. Impact of CYP2D6 on serum concentrations of flupentixol, haloperidol, perphenazine and zuclopenthixol. Br J Clin Pharmacol. 2020. PMID: 33118660. doi:10.1111/bcp.14626

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。